REMARKS

Amendments

In order to expedite prosecution of the current invention, claim 1 has been amended to specifically include the required length of time, which is a minimum of two hours, for subjecting the radioactive seeds to dry heat to effect sterilization. Support for this amendment is presented on page 11, lines 7-9 of the specification. No new matter has been added by the claim amendment herein.

Rejection under 35 U.S.C. § 102(b)

Claims 1-3, 5, 9-10, 12-14, and 18-19 stand rejected under 35 U.S.C. §102(b) as being anticipated by United States Patent No. 5,460,592 to Langton et al ("Langton"). Claim 1 has been amended. Applicants respectfully submit that the amendment does not constitute new matter in contravention of 35 U.S.C. §132. These rejections are respectfully traversed and reconsideration is respectfully requested.

Langton discloses a carrier assembly and method for preparing the carrier assembly for a delivery system for interstitial radiation therapy, and, more particularly, to a carrier assembly in which an elongated member having radioactive seeds therein is disposed. The carrier assembly is heated to provide a semi-rigid elongated member with the carrier assembly being adapted to be shipped to a site of use at which time the semi-rigid elongated

Appl. No. 10/731,828

Amdt. Dated December 20, 2005

Reply to Office action of Sept. 29, 2005

member and seeds may be removed from the carrier assembly for use in interstitial radiation

therapy.

Langton does not disclose the required length of time for subjecting the radioactive

seeds to dry heat to effect sterilization to be at least two hours. As disclosed in Langton on

column 6, lines 1-3, Langton specifies the required length of time to be 1 hour. Furthermore,

Langton does not disclose that the radioactive seeds are free of moisture nor does Langton

disclose that a dose distribution of each radioactive seed is isotropic.

When a claimed invention is not identically disclosed in a reference, and instead

requires picking and choosing among a number of different options disclosed by the

reference, then the reference does not anticipate. Mendenhall v. Astec Industries, Inc., 13

U.S.P.Q.2d 1956 (Fed. Cir. 1989).

In accordance with the aforementioned, Applicants respectfully request that the

Examiner withdrawal the rejections for claims 1-3, 5, 9-10, 12-14, and 18-19 under 35

U.S.C. §102(b) and direct that claims 1-3, 5, 9-10, 12-14, and 18-19 be allowed.

Rejections under 35 USC § 103(a)

Claims 7, 8 and 15 stand rejected under 35 U.S.C. §103(a) as being unpatentable over

United States Patent No. 5,460,592 to Langton et al. Claim 4 stands rejected under 35 U.S.C.

§103(a) as being unpatentable over United States Patent No. 6,106,455 to Kan in view of

Page 5 of 7

Appl. No. 10/731,828

Amdt. Dated December 20, 2005

Reply to Office action of Sept. 29, 2005

United States Patent No. 5,460,592 to Langton et al. These rejections are respectfully

traversed and reconsideration is respectfully requested.

Applicants respectfully disclose that claims 4, 7-8, and 15 are dependent upon an

independent claim or introduce further limitations of another dependent claim that is

dependent on claim 1. In other words, dependent claims 4, 7-8, and 15 will stand or fall

based on independent claim 1. Thus, since independent claim 1 is not rejected under 35

U.S.C. §103(a), Applicants respectfully request withdrawal of the rejection under 35 U.S.C.

§103(a).

Accordingly, Applicants respectfully request that the Examiner withdrawal the

rejections for claims 4, 7-8, and 15 under 35 U.S.C. §103(a) and direct that claims 4, 7-8, and

15 be allowed.

Page 6 of 7

Appl. No. 10/731,828 Amdt. Dated December 20, 2005 Reply to Office action of Sept. 29, 2005

CONCLUSION

Upon entry of this Amendment, claims 1-5, 7-10, 12-15, and 18-19 remain pending. Applicants submit that all outstanding issues have been addressed, and that claims 1-5, 7-10, 12-15, and 18-19 are in condition for allowance, which action is earnestly solicited. Authorization is hereby given to charge any fee which may be due in connection with this communication to Deposit Account 502-665.

Respectfully submitted,

Craig M. Bohlken Reg. No. 32,628

Amersham Health, Inc.
101 Carnegie Center
Princeton, NJ 08540
Phone (609) 514-6530
Fax (609) 514-6572
I:\IP\Response to Office Action\PZ\PZ9918 (12-20-05).doc